SpringWorks Therapeutics Inc. (SWTX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

SpringWorks Therapeutics ... (SWTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

32.49

-4.52 (-12.21%)

At close: Jan 14, 2025, 3:59 PM

33.00

1.57%

Pre-market Jan 15, 2025, 07:06 AM EST

undefined% (undefined)

Bid	32.01
Market Cap	2.42B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.89
PE Ratio (ttm)	-8.35
Forward PE	n/a
Analyst	Buy

Ask	34.99
Volume	2,375,273
Avg. Volume (20D)	1,251,454
Open	37.36
Previous Close	37.01
Day's Range	32.38 - 38.23
52-Week Range	28.21 - 53.92
Beta	undefined

About SWTX

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the t...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 13, 2019

Employees 305

Stock Exchange NASDAQ

Ticker Symbol SWTX

Website https://www.springworkstx.com

Analyst Forecast

According to 6 analyst ratings, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is $69, which is an increase of 112.37% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

SpringWorks Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $63.46M, reflecting a 1.07K% YoY growth and earnings per share of -0.68, making a -53.10% decrease YoY.

Why Price Moved

2 days ago · Source

-13.93%

SpringWorks Therapeutics shares are trading lower ... Unlock content with Pro Subscription

4 days ago · Source

+6.2%

SpringWorks Therapeutics shares are trading higher amid rumors of takeover interest.

News

23 hours ago · zacks.com

SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.

1 day ago · seekingalpha.com

SpringWorks: PDUFA Review Date Could Lead To Next Approved Pipeline Candidate

SpringWorks has shown strong revenue growth with OGSIVEO, achieving a 23% increase from Q2 of 2024 to Q3 of 2024, and potential EMA approval if it could boost sales further. Mirdametinib, a MEK inhibi...

1 week ago · zacks.com

Strength Seen in SpringWorks Therapeutics (SWTX): Can Its 6.0% Jump Turn into More Strength?

SpringWorks Therapeutics (SWTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre...

2 weeks ago · seekingalpha.com

SpringWorks: With Catalyst On The Horizon And Growing Sales, 2025 Looks Great

SpringWorks Therapeutics shows promising growth with their first approved drug and an imminent second approval for mirdametinib in NF1 treatment. SWTX's financials reveal strong cash reserves and grow...

1 month ago · seekingalpha.com

Tarsus Pharmaceuticals & SpringWorks Therapeutics: Jonathan Faison's Top 2 Picks

Jonathan Faison runs the ROTY Biotech Community. Why he's high on Tarsus Pharmaceuticals and his #1 holding, SpringWorks Therapeutics.

1 month ago · zacks.com

SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?

SpringWorks Therapeutics (SWTX) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

Does SpringWorks Therapeutics (SWTX) Have the Potential to Rally 92.68% as Wall Street Analysts Expect?

The mean of analysts' price targets for SpringWorks Therapeutics (SWTX) points to a 92.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreeme...

2 months ago · zacks.com

SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark

SWTX reports mixed third-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

2 months ago · seekingalpha.com

SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX ) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET Company Participants Kim Diamond - Vice President, Corporate Communications Saqib Islam - Chief Executi...

2 months ago · zacks.com

SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $1.27 per share a year ago.

2 months ago · seekingalpha.com

SpringWorks Therapeutics Merits A Speculative Buy

Since we last visited with SpringWorks Therapeutics, Inc. in the summer of 2023, the company has garnered its first FDA approval. That drug has seen encouraging initial sales, and management recently ...